J. Gee

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Julia Margeret Wendy Gee, Julia Gee, Julia M.w. Gee, Julia M Gee, J Gee, J M W Gee, J M Gee, Julia M W Gee, J. M. W. Gee, Julia M. Gee, Julia M. W. Gee, Julia Margaret Wendy Gee, J. M. Gee
Publication record
184 papers · 9,956 citations · H-index 51

PAPERS

Expression of proteins involved in mitochondrial fusion, fission and energy production is altered by age, sex and Alzheimer’s disease
20230 citationsauthor #3
Pyridine based dual binding site aromatase (CYP19A1) inhibitors
20234 citationsauthor #3
The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
20229 citationsauthor #5
Glucocorticoid induced loss of oestrogen receptor alpha gene methylation and restoration of sensitivity to fulvestrant in triple negative breast cancer
20229 citationsauthor #2
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer
202213 citationsauthor #17
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer
20221 citationsauthor #17
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
20221 citationsauthor #24
Epigenome erosion drives neural crest-like phenotypic mimicry in triple-negative breast cancer and other SOX10+ malignancies
20210 citationsauthor #17
Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer
20213 citationsauthor #18
Increased ERb expression during ageing could be neuroprotective against Alzheimer’s disease development in the male but not the female brain
20210 citationsauthor #2
LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
20200 citationsauthor #6
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
2020119 citationsauthor #17
Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance
20201 citationsauthor #9
Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer
201924 citationsauthor #2
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer
201925 citationsauthor #7
MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer
201835 citationsauthor #7
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP
201846 citationsauthor #16
Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer
201663 citationsauthor #10
OP-HMGJ160147 3269..3283
20160 citationsauthor #10
Abstract LB-113: Antihormone-induced expression of BCL3 in estrogen receptor-positive breast cancer drives resistant cell growth
20160 citationsauthor #4
Abstract 1980: Long-range regulation of HOTAIR identifies novel biomarkers of breast cancer outcome and suggests a role in genome instability
20160 citationsauthor #11
Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
201628 citationsauthor #4
A novel role for p21-activated kinase 4 (PAK4) in endocrine resistance and disease progression
20160 citationsauthor #5
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
2015190 citationsauthor #18
Abstract P3-05-19: A new cell panel to study oestrogen receptor loss in acquired endocrine resistant breast cancer
20150 citationsauthor #1
Abstract P3-06-01: Nuclear β-catenin negativity predicts for late relapse in ER+, tamoxifen-treated breast cancer
20150 citationsauthor #4
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells
201563 citationsauthor #40
A new cell panel to study oestrogen receptor loss in acquired endocrine resistant breast cancer
20152 citationsauthor #1
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
2015126 citationsauthor #12
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies
201536 citationsauthor #7
Abstract 738: Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer
20140 citationsauthor #1
Abstract 1617: Quantification of pancreatic cancer proteome & phosphorylome: Indicates molecular events likely contributing to cancer & activation status of drug targets
20140 citationsauthor #9
Abstract 1969: Overexpression of specific CD44 variants mediate endocrine insensitivity and invasion in breast cancer cells
20140 citationsauthor #3
A good drug made better: the fulvestrant dose-response story.
201469 citationsauthor #7
Abstract P1-06-12: The therapeutic sensitivity of ER+/Her2+ breast cancer cells is attenuated in 3D matrix culture and involves switching from AKT to MAPK pathways
20130 citationsauthor #3
Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
201317 citationsauthor #8
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
201347 citationsauthor #10
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
2013420 citationsauthor #34
A gap analysis for breast cancer research: identifying translational priorities
20130 citationsauthor #33
ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer
201284 citationsauthor #26
A review of the biological and clinical characteristics of luminal‐like oestrogen receptor‐positive breast cancer
201228 citationsauthor #4
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2012141 citationsauthor #11
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance
201113 citationsauthor #1
P1-06-18: Loss of E-Cadherin Expression in Clinical Breast Cancer Is Associated with an Adverse Outcome on Tamoxifen.
20114 citationsauthor #10
P1-07-21: Analysis of Molecular Markers by Immunohistochemistry (IHC) Method on Formalin Fixed Paraffin Embedded (FFPE) Tissues Could Predict Shorter Recurrence Free Survival (RFS) and Overall Survival (OS) among Patients Who Have Received Adjuvant Chemotherapy for Early Breast Cancer.
20110 citationsauthor #2
Zinc and cancer
20118 citationsauthor #2
Fulvestrant: analysis of tumour biomarker expression in a combined analysis of pre–surgical studies
20110 citationsauthor #6
ONCOPOOL - a European database for 16,944 cases of breast cancer.
2010120 citationsauthor #7
O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells
20100 citationsauthor #2
Long-term effect of fulvestrant on signaling elements in breast cancer.
20101 citationsauthor #8
18 Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer
20100 citationsauthor #8
Abstract S5-7: Estrogen Receptor Alpha Negative (ER-) Breast Cancer Stem Cells in ER+ Cell Lines and Primary Cancers Are Enriched by Tamoxifen Therapy
20100 citationsauthor #4
Abstract P2-09-37: Immunohistochemical Markers Progesterone Receptor, HER2, Ki67 and bcl-2-Associated Athanogene 1 and Prediction of Adjuvant Tamoxifen Treatment Outcome in ER+ Early Breast Cancer
20102 citationsauthor #1
Abstract P2-06-19: Transferrin Receptor (CD71) Identifies Poor Response to Tamoxifen in Oestrogen Receptor Positive Breast Cancer Patients
20100 citationsauthor #3
The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study
201060 citationsauthor #6
Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71]
20101 citationsauthor #7
182 Long-term effect of fulvestrant on hormone receptors and proliferation marker in breast cancer
20101 citationsauthor #7
Akt-dependent phosphorylation on AIB1 serine 967 contributes to breast cancer tamoxifen resistance.
20099 citationsauthor #3
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
2009236 citationsauthor #13
Experimental Endocrine Resistance: Concepts and Strategies
20090 citationsauthor #5
Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer
20093 citationsauthor #2
Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST).
20094 citationsauthor #6
162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]
20090 citationsauthor #5
Tumor Biomarker Changes Following Pre-Surgical Treatment with 500 mg Fulvestrant Plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone.
200916 citationsauthor #8
Tamoxifen Resistance in Estrogen Receptor Positive (ER+) Breast Cancer Is Driven by Estrogen Receptor Negative (ER-) Cancer Stem-Like Cells.
20090 citationsauthor #3
Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype.
20092 citationsauthor #6
Resistance to HER2-directed trastuzumab therapy in breast cancer
20090 citationsauthor #2
Adverse Features of Acquired Antihormone Resistance and Their Targeting
20091 citationsauthor #6
The dark side of antihormonal action in breast cancer
20093 citationsauthor #1
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis
2008127 citationsauthor #4
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance
200894 citationsauthor #4
Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.
20081 citationsauthor #6
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
2008414 citationsauthor #8
erbB Signalling in breast cancer
20070 citationsauthor #9
Endocrine resistance and breast cancer invasion
20073 citationsauthor #2
Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer
200768 citationsauthor #2
O-55 Assessment of Her-2 status using a panel of antibodies and FISH
20070 citationsauthor #5
O-105 erbB Signalling in breast cancer
20070 citationsauthor #9
Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer
200729 citationsauthor #7
Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer.
20076 citationsauthor #7
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
200764 citationsauthor #7
Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells
20072 citationsauthor #3
Transforming Growth Factor-Â«and Endocrine Sensitivity in Breast Cancer1
20060 citationsauthor #4
Signalling interactions in cancer progression
20060 citationsauthor #2
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.
200660 citationsauthor #7
Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: Co-targeting the EGFR and IGF-1R maximises anti-tumour effects [Abstract]
20065 citationsauthor #2
Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth
2006168 citationsauthor #7
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells
200655 citationsauthor #2
Growth factor receptor interplay and resistance in cancer.
200685 citationsauthor #2
Growth factor pathway switching: implications for the use of gefitinib and trastuzumab
20064 citationsauthor #2
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
200577 citationsauthor #7
Development of strategies for the use of anti-growth factor treatments.
200538 citationsauthor #2
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
2005230 citationsauthor #1
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
200560 citationsauthor #9
Overview of tyrosine kinase inhibitors in clinical breast cancer.
2005106 citationsauthor #3
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
2005196 citationsauthor #4
Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]
20044 citationsauthor #1
Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.
2004104 citationsauthor #5
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib ( ZD 1839 ; Iressa ) in human breast and prostate cancer cells
200414 citationsauthor #3
Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells
2004145 citationsauthor #2

TIMELINE

1990 20 citations

1991 2 citations

1992 10 citations

1993 28 citations

1994 278 citations

1995 160 citations

1996 102 citations

1997 84 citations

1998 155 citations

1999 683 citations

2000 337 citations

2001 2,865 citations

2002 192 citations

2003 191 citations

2004 871 citations

2005 707 citations

2006 377 citations

2007 172 citations

2008 636 citations

2009 274 citations

2010 185 citations

2011 25 citations

2012 253 citations

2013 484 citations

2014 69 citations

2015 417 citations

2016 91 citations

2018 81 citations

2019 49 citations

2020 120 citations

2021 3 citations

2022 33 citations

2023 4 citations

J. Gee

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT